Argus upgrades Novartis to Buy after pullback in shares

As previously reported, Argus analyst David Toung upgraded Novartis (NVS) to Buy from Hold with an $180 price target The firm is citing the company’s “strong volume growth” of 18% in Q4 and high dividend while noting that after the recent pullback in shares, investors face an “attractive entry point”, the analyst tells investors in a research note.